A5021209319- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer and Skin Lesions
- Sarcoma Diagnosis and Treatment
- Breast Lesions and Carcinomas
- Advanced Breast Cancer Therapies
- Parkinson's Disease Mechanisms and Treatments
- Cell Adhesion Molecules Research
- Genetic Neurodegenerative Diseases
- Lymphoma Diagnosis and Treatment
- Bone Tumor Diagnosis and Treatments
- Soft tissue tumor case studies
- Gastrointestinal Tumor Research and Treatment
- Neurological diseases and metabolism
- Salivary Gland Tumors Diagnosis and Treatment
- Gastroesophageal reflux and treatments
- Urologic and reproductive health conditions
- Immunotherapy and Immune Responses
- Parasitic Diseases Research and Treatment
- Ear and Head Tumors
- Colorectal and Anal Carcinomas
- Neurofibromatosis and Schwannoma Cases
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Gastrointestinal disorders and treatments
Institut Gustave Roussy
2017-2025
Assistance Publique – Hôpitaux de Paris
2011-2019
Institut Bergonié
2019
Centre Léon Bérard
2019
Institut Curie
2019
Institut de Cancérologie de l'Ouest
2019
Centre Jean Perrin
2019
Institut Claudius Regaud
2019
Sorbonne Université
2014-2016
Hôpital Charles-Foix
2016
Expression of hormone receptor (HR) for estrogens (ER) and progesterone (PR) HER2 remains the cornerstone to define therapeutic strategy breast cancer patients. We aimed compare phenotypic profiles between matched primary metastatic (MBC) in ESME database, a National real-life multicenter cohort MBC Patients with results available on both tumour disease within 6 months diagnosis before any progression were eligible main analysis. Among 16,703 patients included 1677 (10.0%) had biopsy at...
Real-world data on indications of Oncotype DX® testing (RS) and its impact adjuvant chemoendocrine therapy (CET) use in early-stage BC pN0/1 patient (pt) subpopulations across multiple French centers are limited. We conducted a comprehensive retrospective observational study characteristics, management practices, therapeutic decision RS results. 952 pts underwent testing, including 420 2 private clinics (Apr 2014 – Dec 2023), 505 at Gustave Roussy Institute (Nov 2020 2023). Pt...
Abstract Background: Therapeutic options at diagnosis for metastatic breast cancers (MBC) differ largely according to cancer phenotype (namely, hormone receptor (HR) and HER2 status). Reported discordance rates between primary tumor metastasis vary widely in literature, with a median of 18% estrogen receptor, 31% progesterone 10% HER2. The present study aimed compare phenotypic profiles MBC the real-life setting. Patients (pts) methods: Epidemio-Strategy Medical Economics (ESME)MBC data...
Mammary pleomorphic adenoma is a biphasic tumor, characterized by epithelial-myoepithelial components with myxochondroid stroma, resembling the prototypic of salivary glands. We report multiple diagnostic pitfalls raised mammary adenoma, initially diagnosed as mucinous carcinoma on fine-needle aspiration (FNA) cytology and invasive needle core biopsy. The final diagnosis was made surgical specimen. As term “pleomorphic” suggests, this tumor can present various phenotypes, some which might be...